Results 121 to 130 of about 8,366 (155)

Ceftazidime/avibactam‐induced severe neutropenia: A case report

British Journal of Clinical Pharmacology, 2023
AbstractCeftazidime/avibactam is an important option for the treatment of infections caused by multidrug‐resistant gram‐negative bacteria. Haematological abnormalities are rare adverse events. We describe a case of a 63‐year‐old male who developed severe neutropenia following exposure to ceftazidime/avibactam in the intensive care unit for the ...
Weifang Wu, Yangxiao Lai, Yiheng Lin, Tong Li   +3 more
openaire   +2 more sources

In Vitro Comparison of Aztreonam/Amoxicillin-Clavulanate Versus Aztreonam/Ceftazidime-Avibactam on Ceftazidime-Avibactam Resistant Stenotrophomonas maltophilia

Microbial Drug Resistance, 2022
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Lise Crémet, Léo Joffraud, Emmanuel Eschapasse, Tiphaine Bihouée, Adrien Tissot, Sophie Gibaud, Elise Persyn   +6 more
openaire   +3 more sources

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

International Journal of Antimicrobial Agents, 2014
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow, Linda G, Otterson, Michael D, Huband, Kevin M, Krause, Wright W, Nichols   +4 more
openaire   +2 more sources

Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections

The Consultant Pharmacist, 2015
To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosing, and administration of ceftazidime/avibactam (CAZ/AVI).A search of PubMed using the terms "ceftazidime," "avibactam," "NXL104," and "AVE1330A" was performed. The manufacturer's website was also reviewed to further identify relevant
Elias B, Chahine, Mariette, Sourial, Raquel, Ortiz   +2 more
openaire   +2 more sources

Ceftazidime/avibactam serum concentration in patients on ECMO

Journal of Antimicrobial Chemotherapy
Abstract Objectives The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure.
Anaïs Curtiaud, Matthieu Petit, Juliette Chommeloux, Marc Pineton de Chambrun, Guillaume Hekimian, Matthieu Schmidt, Alain Combes, Charles-Edouard Luyt   +7 more
openaire   +2 more sources

Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation

Transplantation Proceedings, 2020
After lung transplantation (LTx), infections caused by multidrug-resistant (MDR) bacteria are frequent and difficult to treat. Some new antibiotics seem to be effective in treating these infections.We describe our experience in treatment of Klebsiella pneumoniae MDR and Pseudomonas aeruginosa MDR infections with ceftazidime-avibactam (CEF-AVI) and ...
Amore D., Pecoraro Y., Carillo C., Russo G., Poggi C., Anile M., Pagini A., Bassi M., Cagnetti S., Mottola E., D'Agostino F. G., Vannucci J., Mantovani S., Pugliese F., De Giacomo T., Rendina E. A., Venuta F., Diso D.   +17 more
openaire   +2 more sources

Therapeutic insights: Use of ceftazidime‐avibactam in pediatric patients

Pediatrics International
Abstract Background The increasing worldwide prevalence of multidrug‐resistant (MDR) bacteria underscores the pressing demand for innovative therapeutic solutions. Ceftazidime‐avibactam (CAZ‐AVI) represents a promising new drug combination that has received approval for specific infection types.
Özge Metin Akcan, Mustafa Gençeli, Talha Üstüntaş, Abdullah Akkuş, Sevgi Pekcan, Metin Doğan   +5 more
openaire   +2 more sources

Ceftazidime-avibactam use in hematology patients: single-center experience

European Journal of Clinical Microbiology & Infectious Diseases
To investigate the efficacy of the cephalosporin/ beta lactamase inhibitor combination ceftazidime-avibactam in hematology patients with hematopoietic stem cell transplantation or receiving chemotherapy alone.In this study, 80 patients who were followed up in the Stem Cell Transplant Center and Hematology Clinic of Istinye University Gaziosmanpaşa ...
Aysun, Halacoglu, Mustafa, Koroglu, Mehmet, Ozen   +2 more
openaire   +2 more sources

Safety evaluation of ceftazidime/avibactam based on FAERS database

Infection
To explore adverse event (AE) signals of Ceftazidime/avibactam (CZA) based on the FDA Adverse Event Reporting System (FAERS) database.AE reports primarily associated with CZA were retrieved from the FAERS database from the second quarter of 2015 to the second quarter of 2023.
Xiuhong, Zhang, Ying, Jiang, Yating, Guo, Wenbo, Zhou, Weizhen, Qiao, Haohao, Zhu, Zhigang, Qi   +6 more
openaire   +2 more sources

Studying ceftazidime-avibactam in selected populations

The Lancet Infectious Diseases, 2016
Florian M E, Wagenlehner, Kurt G, Naber
openaire   +2 more sources